1
|
Birkeland P, Hansen V, Tharmabalan V, Lauritsen J, Nielsen T, Truelsen T, Rosenbaum S, von Weitzel-Mudersbach P. Long-term stroke risk in Moyamoya disease. Int J Stroke 2024; 19:452-459. [PMID: 37950387 DOI: 10.1177/17474930231216037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2023]
Abstract
BACKGROUND Moyamoya disease (MMD) is considered a progressive disease with an ongoing risk of recurrent stroke. However, there is a lack of long-term observational data to quantify the extent of the stroke risk. METHODS This study aimed to provide insight into the long-term stroke risk in MMD and explore possible risk factors for stroke. Records from all patients diagnosed with MMD in 13 clinical departments from 6 different Danish hospitals between 1994 and 2017 were retrospectively reviewed until 2021. RESULTS The cohort comprised 50 patients (33 females and 17 males). Patients were followed up for a median of 9.4 years, with more than 10 years of follow-up for 24 patients. Ten patients had 11 new stroke events-6 ischemic strokes and 5 brain hemorrhages. Events occurred at a median of 7 years and up to 25 years after diagnosis. The overall Kaplan-Meier 5-year stroke risk was 10%. Patients with bypass performed had significantly fewer events than conservatively treated patients (HR 0.25, 95% confidence interval (CI) 0.07-0.91, p < 0.05). All but one event occurred in females, a difference that reached statistical significance. CONCLUSIONS The study provides data on the extent of the risk of recurrent stroke in MMD. Bypass surgery patients had fewer stroke events than those treated conservatively. There was a trend toward a higher stroke risk in females. DATA ACCESS STATEMENT The data supporting this study's findings are available from the corresponding author upon reasonable request.
Collapse
Affiliation(s)
- Peter Birkeland
- Department of Neurosurgery, Copenhagen University Hospital, København Ø, Denmark
| | - Victoria Hansen
- Department of Neurology, Aalborg University Hospital, Aalborg, Denmark
| | - Vinosha Tharmabalan
- Department of Neurosurgery, Copenhagen University Hospital, København Ø, Denmark
| | - Jens Lauritsen
- Department of Orthopaedic Surgery, Odense University Hospital, Odense, Denmark
- Department of Clinical Research, University of Southern Denmark, Denmark
| | - Troels Nielsen
- Department of Neurosurgery, Odense University Hospital, Odense C, Denmark
| | - Thomas Truelsen
- Department of Neurology, Copenhagen University Hospital, København Ø, Denmark
| | - Sverre Rosenbaum
- Department of Neurology, Bispebjerg Hospital, København, Denmark
| | | |
Collapse
|
2
|
Henning JSL, Fernandez EJ, Nielsen T, Hazel S. Play and welfare in domestic cats: Current knowledge and future directions. Anim Welf 2022. [DOI: 10.7120/09627286.31.4.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Play and welfare have long been linked within animal research literature, with play considered as both a potential indicator and promoter of welfare. An indicator due to observations that play is exhibited most frequently in times when an animal's fitness is not under threat and when
immediate needs such as food, water and adequate space are met. And a promoter, because of observations that animals who play more also have better welfare outcomes. However, limited research has been undertaken to investigate this link, especially in companion animals. The domestic cat (
Felis catus) is one of the most popular companion animals in the world, yet little is known about the impact of play behaviour on cat welfare. We review the current literature on play and welfare in cats. This includes examining the role of cat play in mitigating negative welfare outcomes,
such as reducing problem behaviours, one of the leading reasons for guardian dissatisfaction and cat relinquishment to shelters. Play is also discussed as a potential tool to provide environmental enrichment and to improve cat-human relationships. Future areas for research are suggested. We
find that further research is needed that uses a multifaceted approach to assess how quantity, type and quality of play impact subsequent cat behaviour and welfare. Future research could also assess cat play needs and preferences as well as investigate the role of play in mitigating threats
to cat welfare such as reducing problem behaviour and improving human-cat relationships. If play is an indicator and promoter of welfare, studies into the impact of play may offer an accessible approach for monitoring and improving domestic cat welfare.
Collapse
Affiliation(s)
- JSL Henning
- University of Adelaide, School of Animal and Veterinary Sciences, South Australia, Australia
| | - EJ Fernandez
- University of Adelaide, School of Animal and Veterinary Sciences, South Australia, Australia
| | - T Nielsen
- University of Adelaide, School of Animal and Veterinary Sciences, South Australia, Australia
| | - S Hazel
- University of Adelaide, School of Animal and Veterinary Sciences, South Australia, Australia
| |
Collapse
|
3
|
Chan VWS, Keeley F, Lagerveld B, Breen D, King A, Nielsen T, van Strijen M, Garnon J, Alcorn D, Graumann O, de Kerviler E, Zondervan P, Walkden M, Lughezzani G, Wah TM. 455 The Changing Trends of Image Guided Biopsy of Small Renal Masses Before Intervention- an Analysis of European Multinational Prospective EuRECA Registry. Br J Surg 2022. [DOI: 10.1093/bjs/znac269.502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Abstract
Aim
To evaluate the use of pre-cryoablation biopsy for small renal masses (SRMs) and the effects of increasing up take on histological results of treated SMRs.
Method
From 2015 to 2019, patients with sporadic T1N0M0 SRMs undergoing percutaneous, laparoscopic or open cryoablation from 14 European institutions within the European Registry For Renal Cryoablation (EuRECA) were included for the retrospective analysis. Univariate and multivariate logistic models were used to evaluate the trends, histological results and the factors influencing use of pre-cryoablation biopsy.
Results
871 patients (Median [IQR] age, 69[14], 298 women) undergoing cryoablation were evaluated. The use of pre-cryoablation biopsy has significantly increased from 42% (65/156) in 2015 to 72% (88/122) in 2019 (p<0.001). Patients treated for a benign histology are significantly more likely to have presented later in the trend, where pre-cryoablation biopsy is more prevalent (OR: 0.64, 95% CI 0.51–0.81, p<0.001). Patients treated for undiagnosed histology are also significantly less likely to have presented in 2018 compared to 2016 (OR 0.31, 95% CI 0.10–0.97, p=0.044). Patients aged 70+ are less likely to be biopsies pre-cryoablation (p<0.05). R.E.N.A.L. nephrometry score of 10+ and a Charlson Comorbidity Index >1 are factors associated with lower likelihood to not have received a pre-cryoablation biopsy (p<0.05).
Conclusion
An increased use of pre-cryoablation biopsy was observed and cryoablation patients treated with a benign histology is more likely to have presented in periods where pre-cryoablation biopsy is not as prevalent. Comparative studies are needed to draw definitive conclusions on the effect of pre-cryoablation biopsy on SRM treatments.
Collapse
Affiliation(s)
- VWS Chan
- School of Medicine, Faculty of Medicine and Health, University of Leeds , Leeds , United Kingdom
- Department of Targeted Intervention, Division of Surgery and Interventional Science, University College London , London , United Kingdom
| | - F Keeley
- Bristol Urological Institute, North Bristol NHS Trust , Bristol , United Kingdom
| | - B Lagerveld
- Department of Urology, OLVG , Amsterdam , Netherlands
| | - D Breen
- Department of Radiology, Southampton University Hospitals , Southampton , United Kingdom
| | - A King
- Department of Radiology, Southampton University Hospitals , Southampton , United Kingdom
| | - T Nielsen
- Department of Urology, Aarhus University Hospital , Aarhus , Denmark
| | - M van Strijen
- Department of Radiology, St Antonius Hospital , Nieuwegein , Netherlands
| | - J Garnon
- Department of Interventional Radiology , Nouvel Hôpital Civil, 1 place de l’Hôpital 67000 Strasbourg , France
| | - D Alcorn
- Department of Interventional Radiology, Gartnavel General Hospital , Glasgow , United Kingdom
| | - O Graumann
- Department of Radiology, Odense University Hospital , Odense , Denmark
| | - E de Kerviler
- Radiology Department, Saint-Louis Hospital , Paris , France
| | - P Zondervan
- Department of Urology , 26066 Amsterdam UMC, , Amsterdam , Netherlands
- University of Amsterdam , 26066 Amsterdam UMC, , Amsterdam , Netherlands
| | - M Walkden
- Department of Imaging, University College London Hospitals NHS Foundation Trust , London , United Kingdom
| | - G Lughezzani
- Vita-Salute San Raffaele University, Department of Urology , Milan , Italy
| | - TM Wah
- Department of Diagnostic and Interventional Radiology, Institute of Oncology, Leeds Teaching Hospitals Trust, St James’s University Hospital , Leeds , United Kingdom
| |
Collapse
|
4
|
Antoniotti C, Boccaccino A, Seitz R, Giordano M, Rossini D, Ambrosini M, Salvatore L, McGregor K, Bergamo F, Conca V, Leonetti S, Provenzano L, Tamberi S, Ramundo M, Tortora G, Rasola C, Ross D, Passardi A, Nielsen T, Varga M, Cremolini C. SO-36 An immune-related gene expression profile predicts the efficacy of adding atezolizumab to first-line FOLFOXIRI/bevacizumab in metastatic colorectal cancer: A translational analysis of the phase II randomized AtezoTRIBE study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
5
|
Varga M, Nielsen T, Vidal G, Hout D, Ross D, Seitz R, Schweitzer B. P60.10 A 27-Gene IO Assay to Capture the Tumor Immune Microenvironment Is Associated With Response in Metastatic and Primary Tumors. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
6
|
Nøhr AK, Lindow M, Forsingdal A, Demharter S, Nielsen T, Buller R, Moltke I, Vitezic M, Albrechtsen A. A large-scale genome-wide gene expression analysis in peripheral blood identifies very few differentially expressed genes related to antidepressant treatment and response in patients with major depressive disorder. Neuropsychopharmacology 2021; 46:1324-1332. [PMID: 33833401 PMCID: PMC8134553 DOI: 10.1038/s41386-021-01002-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/05/2020] [Revised: 02/20/2021] [Accepted: 03/09/2021] [Indexed: 11/08/2022]
Abstract
A better understanding of the biological factors underlying antidepressant treatment in patients with major depressive disorder (MDD) is needed. We perform gene expression analyses and explore sources of variability in peripheral blood related to antidepressant treatment and treatment response in patients suffering from recurrent MDD at baseline and after 8 weeks of treatment. The study includes 281 patients, which were randomized to 8 weeks of treatment with vortioxetine (N = 184) or placebo (N = 97). To our knowledge, this is the largest dataset including both gene expression in blood and placebo-controlled treatment response measured by a clinical scale in a randomized clinical trial. We identified three novel genes whose RNA expression levels at baseline and week 8 are significantly (FDR < 0.05) associated with treatment response after 8 weeks of treatment. Among these genes were SOCS3 (FDR = 0.0039) and PROK2 (FDR = 0.0028), which have previously both been linked to depression. Downregulation of these genes was associated with poorer treatment response. We did not identify any genes that were differentially expressed between placebo and vortioxetine groups at week 8 or between baseline and week 8 of treatment. Nor did we replicate any genes identified in previous peripheral blood gene expression studies examining treatment response. Analysis of genome-wide expression variability showed that type of treatment and treatment response explains very little of the variance, a median of <0.0001% and 0.05% in gene expression across all genes, respectively. Given the relatively large size of the study, the limited findings suggest that peripheral blood gene expression might not be the best approach to explore the biological factors underlying antidepressant treatment.
Collapse
Affiliation(s)
- Anne Krogh Nøhr
- The Bioinformatics Centre, Department of Biology, University of Copenhagen, Copenhagen N, Denmark.
- H. Lundbeck A/S, Valby, Copenhagen, Denmark.
| | | | | | | | | | | | - Ida Moltke
- The Bioinformatics Centre, Department of Biology, University of Copenhagen, Copenhagen N, Denmark
| | | | - Anders Albrechtsen
- The Bioinformatics Centre, Department of Biology, University of Copenhagen, Copenhagen N, Denmark
| |
Collapse
|
7
|
Hout D, Nielsen T, Schweitzer B, Seitz R, Vidal G. PR01.04 A Novel Immunomodulatory Signature Improves Prediction of Response to Immunotherapy Compared to PD-L1 IHC in NSCLC Patients. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2020.10.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
8
|
Hout D, Seitz R, Bailey D, Schweitzer B, Nielsen T, Vidal G. PR01.03 A Novel 27-Gene Signature Associated with Better Outcomes for NSCLC Patients Treated with IO Therapies with PD-L1 Expression >50%. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2020.10.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
9
|
Jaafar R, Ødegård J, Mathiessen H, Karami AM, Marana MH, von Gersdorff Jørgensen L, Zuo S, Nielsen T, Kania PW, Buchmann K. Quantitative trait loci (QTL) associated with resistance of rainbow trout Oncorhynchus mykiss against the parasitic ciliate Ichthyophthirius multifiliis. J Fish Dis 2020; 43:1591-1602. [PMID: 32944955 PMCID: PMC7692903 DOI: 10.1111/jfd.13264] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Revised: 08/20/2020] [Accepted: 08/23/2020] [Indexed: 06/11/2023]
Abstract
The parasitic ciliate Ichthyophthirius multifiliis has a low host specificity eliciting white spot disease (WSD) in a wide range of freshwater fishes worldwide. The parasite multiplies rapidly whereby the infection may reach problematic levels in a host population within a few days. The parasite targets both wild and cultured fish but the huge economic impact of the protozoan is associated with mortality, morbidity and treatment in aquacultural enterprises. We have investigated the potential for genetic selection of WSD-resistant strains of rainbow trout. Applying the DNA typing system Affymetrix® and characterizing the genome of the individual fish by use of 57,501 single nucleotide polymorphisms (SNP) and their location on the rainbow trout chromosomes, we have genetically characterized rainbow trout with different levels of natural resistance towards WSD. Quantitative trait loci (QTL) used for the selection of breeders with specific markers for resistance are reported. We found a significant association between resistance towards I. multifiliis infection and SNP markers located on the two specific rainbow trout chromosomes Omy 16 and Omy 17. Comparing the expression of immune-related genes in fish-with and without clinical signs-we recorded no significant difference. However, trout surviving the infection showed high expression levels of genes encoding IgT, T-cell receptor TCRβ, C3, cathelicidins 1 and 2 and SAA, suggesting these genes to be associated with protection.
Collapse
Affiliation(s)
- R Jaafar
- Laboratory of Aquatic PathobiologyDepartment of Veterinary and Animal SciencesFaculty of Health and Medical SciencesUniversity of CopenhagenFrederiksberg C.Denmark
| | | | - H Mathiessen
- Laboratory of Aquatic PathobiologyDepartment of Veterinary and Animal SciencesFaculty of Health and Medical SciencesUniversity of CopenhagenFrederiksberg C.Denmark
| | - A M Karami
- Laboratory of Aquatic PathobiologyDepartment of Veterinary and Animal SciencesFaculty of Health and Medical SciencesUniversity of CopenhagenFrederiksberg C.Denmark
| | - M H Marana
- Laboratory of Aquatic PathobiologyDepartment of Veterinary and Animal SciencesFaculty of Health and Medical SciencesUniversity of CopenhagenFrederiksberg C.Denmark
| | - L von Gersdorff Jørgensen
- Laboratory of Aquatic PathobiologyDepartment of Veterinary and Animal SciencesFaculty of Health and Medical SciencesUniversity of CopenhagenFrederiksberg C.Denmark
| | - S Zuo
- Laboratory of Aquatic PathobiologyDepartment of Veterinary and Animal SciencesFaculty of Health and Medical SciencesUniversity of CopenhagenFrederiksberg C.Denmark
| | | | - P W Kania
- Laboratory of Aquatic PathobiologyDepartment of Veterinary and Animal SciencesFaculty of Health and Medical SciencesUniversity of CopenhagenFrederiksberg C.Denmark
| | - K Buchmann
- Laboratory of Aquatic PathobiologyDepartment of Veterinary and Animal SciencesFaculty of Health and Medical SciencesUniversity of CopenhagenFrederiksberg C.Denmark
| |
Collapse
|
10
|
Picard-Deland C, Pastor M, Solomonova E, Paquette T, Nielsen T. 0088 Gravity Dreams Following a Virtual Reality Flight Simulation. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Flying is a prevalent but infrequent experience in dreams. Despite a broad interest in such unique dream experiences, there is still no experimental procedure for reliably inducing them. Our study aimed 1) to induce flying dreams in the laboratory using virtual reality (VR), 2) to examine phenomenological correlates of flying dreams, such as lucidity and emotions and 3) to investigate the dynamics of dreamed gravity imagery in relation to participant state and trait factors.
Methods
A total of 137 healthy participants (24.01±4.03 y.o.; 85 F; 52 M) took part in a custom-built immersive VR task in which they learn how to ‘fly’ as precisely and quickly as possible, engaging vestibular, motor and visuo-spatial systems. Dreams were collected a) from home dream journals for 5 days before and 10 days after the laboratory VR task and b) after a 90-min morning nap in laboratory. Dream reports were scored by 2 independent judges for flying and other gravity-related imagery. Linear mixed models statistics were used to compare dreams from this cohort with a separate control cohort (N=52) that followed a similar protocol in the same lab but did not undertake a virtual flying task.
Results
The VR task successfully increased the likelihood of experiencing flying in dreams from both the laboratory nap (7.1%) and the following night (10.6%) compared to baseline (1.3%) and the control cohort on those days (Lab: 2.4%; following night: 0%). In contrast, the occurrence of other gravity imagery showed no differences. Flying dreams were altered qualitatively, exhibiting higher levels of lucid-control and emotional intensity after VR exposure. Moreover, various factors such as sex, prior dream experiences and sensory immersion in VR differentially modulated flying dream induction.
Conclusion
Our findings provide both quantitative and qualitative insights into flying dreams that may facilitate understanding of these typical dream experiences and future developments in dream flight-induction technologies.
Support
Natural Sciences and Engineering Research Council of Canada
Collapse
Affiliation(s)
- C Picard-Deland
- Université de Montréal, Neuroscience Department, Montreal, QC, CANADA
| | - M Pastor
- Dream & Nightmare Laboratory; Center for Advanced Research in Sleep Medicine, Montreal, QC, CANADA
| | - E Solomonova
- McGill University; Department of Psychiatry, Montreal, QC, CANADA
| | - T Paquette
- Dream & Nightmare Laboratory; Center for Advanced Research in Sleep Medicine, Montreal, QC, CANADA
| | - T Nielsen
- Dream & Nightmare Laboratory; Center for Advanced Research in Sleep Medicine, Montreal, QC, CANADA
| |
Collapse
|
11
|
Powell R, Nielsen T. The relationship of nightmares, insomnia, cataplexy, mirror behaviors, and psychological distress to suicidal ideation in undergraduate students. Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
12
|
Hinerfeld D, Chumsri S, Asleh K, Brauer H, Kachergus J, Lauttia S, Lindman H, Nielsen T, Joensuu H, Thompson A. Effects of immune architecture on response to adjuvant capecitabine in triple negative breast cancer (FinXX trial). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Morschhauser F, Ghosh N, Lossos I, Palomba M, Mehta A, Casasnovas O, Stevens D, Chitra S, Knapp A, Nielsen T, Oestergaard M, Wenger M, Salles G. EFFICACY AND SAFETY OF OBINUTUZUMAB + LENALIDOMIDE + ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.74_2629] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- F. Morschhauser
- Institute of Hematology-Transfusion; Centre Hospitalier Régional Universitaire de Lille; Lille France
| | - N. Ghosh
- Hematologic Oncology and Blood Disorders; Levine Cancer Institute/Atrium Health; Charlotte NC United States
| | - I. Lossos
- Division of Hematology; Department of Medicine, University of Miami; Miami FL United States
| | - M.L. Palomba
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York NY United States
| | - A. Mehta
- Division of Hematology and Oncology; University of Alabama School of Medicine; Birmingham Alabama United States
| | - O. Casasnovas
- Service d'Hématologie clinique; CHU Dijon Bourgogne - Hôpital François Mitterrand; Dijon France
| | - D. Stevens
- Norton Cancer Institute; Norton Healthcare; Louisville KY United States
| | - S. Chitra
- Product Development Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - A. Knapp
- Product Development Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - T. Nielsen
- Product Development Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - M. Oestergaard
- Oncology Biomarker Development; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - M. Wenger
- Product Development Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - G. Salles
- Haematology Department; Université Claude Bernard de Lyon, Lyon University Hospital; Villeurbanne France
| |
Collapse
|
14
|
Berry D, Broglio K, Ward C, Sahin D, Nielsen T, Mattiello F, McGlothlin A, Wendelberger B, Foster M, Nowakowski G, Kostakoglu L. PET-CR AS A SURROGATE FOR SURVIVAL OUTCOMES IN DLBCL: A LITERATURE BASED META-ANALYSIS. Hematol Oncol 2019. [DOI: 10.1002/hon.59_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- D.A. Berry
- Biostatistics; M.D. Anderson Cancer Center; Houston TX United States
| | - K.R. Broglio
- Biostatistics; Berry Consultants, LLC; Austin United States
| | - C. Ward
- PDBB; F. Hoffmann-La Roche Ltd.; Basel Switzerland
| | - D. Sahin
- PDO; F. Hoffmann-La Roche Ltd., BASEL; Switzerland
| | - T. Nielsen
- PDO; F. Hoffmann-La Roche Ltd., BASEL; Switzerland
| | - F. Mattiello
- PDBB; F. Hoffmann-La Roche Ltd.; Basel Switzerland
| | | | | | - M. Foster
- Biostatistics; Berry Consultants, LLC; Austin United States
| | - G.S. Nowakowski
- Lymphoma Group; Mayo Clinic Rochester; Rochester United States
| | - L. Kostakoglu
- Radiology; Icahn School of Medicine at Mount Sinai; NY United States
| |
Collapse
|
15
|
Chauvie S, Dalmasso F, Pierce L, Vitolo U, Martelli M, Sehn L, Trněný M, Nielsen T, Sahin D, Lee C, Mattiello F, Berchialla P, Kinahan P, Kostakoglu L. RADIOMICS INCREASE THE PROGNOSTIC VALUE OF CLINICAL AND PET RISK FACTORS IN DLBCL: RESULTS FROM THE PHASE 3 GOYA STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.21_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- S. Chauvie
- Medical Physics Division; Santa Croce e Carle Hospital; Cuneo Italy
| | - F. Dalmasso
- Medical Physics Division; Santa Croce e Carle Hospital; Cuneo Italy
| | - L. Pierce
- Department of Radiology; University of Washington; Seattle WA United States
| | - U. Vitolo
- Department of Oncology and Haematology; Azienda Ospedaliera-Universitaria Città della Salute e della Scienza; Turin Italy
| | - M. Martelli
- Department of Translational and Precision Medicine; Sapienza University of Rome; Rome Italy
| | - L.H. Sehn
- Medical Oncology; University of British Columbia; Vancouver Canada
| | - M. Trněný
- 1st Department of Medicine - Department of Haematology; Charles University General Hospital; Prague Czech Republic
| | - T. Nielsen
- Product Development Oncology; F. Hoffmann-La Roche Ltd.; Basel Switzerland
| | - D. Sahin
- Product Development Oncology; F. Hoffmann-La Roche Ltd.; Basel Switzerland
| | - C. Lee
- Product Development Oncology; Genentech, Inc.; South San Francisco United States
| | - F. Mattiello
- Product Development Oncology; F. Hoffmann-La Roche Ltd.; Basel Switzerland
| | - P. Berchialla
- Clinical and Biological Sciences; University of Turin; Turin Italy
| | - P.E. Kinahan
- Department of Radiology; University of Washington; Seattle WA United States
| | - L. Kostakoglu
- Department of Radiology; Icahn School of Medicine; New York United States
| |
Collapse
|
16
|
Trněný M, Canales Ruiz I, Martelli M, Sehn L, Vitolo U, Brown H, Nielsen T, Sellam G, Kostakoglu L. BASELINE TOTAL METABOLIC TUMOUR VOLUME IS HIGHLY PROGNOSTIC FOR REFRACTORINESS TO IMMUNOCHEMOTHERAPY IN DLBCL: AN ANALYSIS OF THE PHASE 3 GOYA TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.20_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Trněný
- 1st Department of Medicine - Department of Haematology; Charles University, General Hospital; Prague Czech Republic
| | - I. Canales Ruiz
- Product Development Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - M. Martelli
- Department of Translational and Precision Medicine; Sapienza University of Rome; Rome Italy
| | - L.H. Sehn
- Medical Oncology; University of British Columbia; Vancouver Canada
| | - U. Vitolo
- Department of Oncology and Haematology; Azienda Ospedaliera-Universitaria Città della Salute e della Scienza; Turin Italy
| | - H. Brown
- on assignment to Roche Products Ltd; Welwyn Garden City; United Kingdom
| | - T. Nielsen
- Product Development Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - G. Sellam
- Product Development Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - L. Kostakoglu
- Department of Radiology; Icahn School of Medicine at Mount Sinai; New York United States
| |
Collapse
|
17
|
Cheng AS, Leung SC, Gao D, Anurag M, Nielsen T, Ellis MJ. Abstract P1-06-02: Mismatch repair protein loss in breast cancer: Clinicopathological associations in a large British Columbia cohort. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-06-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Alterations to mismatched repair (MMR) pathways are a known cause of cancer (particularly colorectal and endometrial). Recently, the FDA approved pembrolizumab for use in MMR-deficient (MMRD) cancers of any type, and the diagnosis can be made by immunohistochemistry (IHC) or genomic methods. In breast cancer, mutational process analyses indicate MMRD occurs in about 2% of breast cancer (Cancer Res; 77; 4755-62, 2017) and recent functional studies have shown associations with resistance to endocrine therapy and sensitivity to CDK4/6 inhibitors (Cancer Discov; 7; 1168-83, 2017). To date, insufficient cases have been assembled to power meaningful associative or survival studies. Herein, the strong correlation between IHC-determined loss of MLH1, PMS2, MSH2 or MSH6 and genomic evidence allowed the assessment of MMRD on a large tissue microarray (TMA) series linked to detailed biomarkers and long-term outcome data.
Methods: IHC markers MLH1, PMS2, MSH2 and MSH6 were optimized on the Ventana automated stainer for application to breast cancer TMAs. The patient cohort consists of females from British Columbia diagnosed with primary invasive breast carcinoma in 1986-1992, referred to the British Columbia Cancer Agency for treatment and follow-up. TMA blocks were sectioned and stained. Slides were scored by a pathologist and only nuclear positivity was evaluated positive. Loss of nuclear positivity for any one of the four tested marker defined MMRD. Clinicopathological associations were tested by Chi-square, and survival by Kaplan-Meier plot with log rank test.
Result: 1635 cases were interpretable for all MMR markers. 31 cases (1.9%) met criteria for MMRD. 6 cases had paired losses (4 MLH1-PMS2 loss, 2 MSH2-MSH6 loss) and the remaining 25 cases had singular MMR loss (11 PMS2 loss, 10 MLH1 loss, 3 MSH6 loss, 1 MSH2 loss). Deficiency of the the MutL complex (MLH1/PMS2) predominated over the MutS complex (MSH2/MSH6).
Among the demographic and pathological variables assessed – age, grade, tumour size, lymphovascular invasion, nodal and menstrual status – high grade is associated with MMRD (p=0.014). In terms of biomarker, MMRD is significantly associated with PR negativity (p=0.003) and PD-L1 expression (p=0.049), but not with ER, Her2, Ki67, or basal breast cancer IHC markers, nor does MMRD significantly correlate with any of the established major intrinsic subtypes of breast cancer. Tumor infiltrating lymphocyte (TIL) counts are higher in MMRD cases (p=0.009). Although statistically not significant (small numbers), Kaplan-Meier plots of survival analysis demonstrated a trend for MMR loss to be associated with decreased breast cancer disease-specific and overall survival.
Conclusion: This large series assessed by IHC corroborates findings from smaller genomic series that MMRD is present in about 2% of breast cancers. MMRD tumors are more likely to be high grade, low PR and immunologically active (higher PD-L1 expression and TIL counts). MMR deficiency is present across all major molecular subtypes (luminal, HER2, basal). Given the efficacy of PD1/PDL1 targeting agents in MMR deficient tumors of other types, evidence for the activity of these agents in MMR deficient breast cancers should be actively sought.
Citation Format: Cheng AS, Leung SC, Gao D, Anurag M, Nielsen T, Ellis MJ. Mismatch repair protein loss in breast cancer: Clinicopathological associations in a large British Columbia cohort [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-06-02.
Collapse
Affiliation(s)
- AS Cheng
- Genetic Pathology Evaluation Center, Vancouver, BC, Canada; Baylor College of Medicine, Houston, TX
| | - SC Leung
- Genetic Pathology Evaluation Center, Vancouver, BC, Canada; Baylor College of Medicine, Houston, TX
| | - D Gao
- Genetic Pathology Evaluation Center, Vancouver, BC, Canada; Baylor College of Medicine, Houston, TX
| | - M Anurag
- Genetic Pathology Evaluation Center, Vancouver, BC, Canada; Baylor College of Medicine, Houston, TX
| | - T Nielsen
- Genetic Pathology Evaluation Center, Vancouver, BC, Canada; Baylor College of Medicine, Houston, TX
| | - MJ Ellis
- Genetic Pathology Evaluation Center, Vancouver, BC, Canada; Baylor College of Medicine, Houston, TX
| |
Collapse
|
18
|
Crusell M, Hansen T, Nielsen T, Allin K, Ruehlemann M, Damm P, Vestergaard H, Roerbye C, Joergensen N, Christiansen O, Heinsen FA, Franke A, Hansen T, Lauenborg J, Pedersen O. Gestational diabetes is associated with an aberrant gut microbiota during pregnancy and postpartum. J Reprod Immunol 2018. [DOI: 10.1016/j.jri.2018.05.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
19
|
Schytte T, Nielsen T, Moeller D, Hoffmann L, Khalil A, Knap M, Lund M, Nyhus C, Hansen T, Ottosson W, Borissova S, Appelt A, Brimk C, Hansen O. PO-0754: Safe inhomogeneus RT dose escalation in locally advanced NSCLC, -interim results from NARLAL2. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31064-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
20
|
Printz T, Pedersen ER, Juhl P, Nielsen T, Grøntved ÅM, Godballe C. Reproducibility of Dual-Microphone Voice Range Profile Equipment. J Speech Lang Hear Res 2017; 60:3369-3377. [PMID: 29121160 DOI: 10.1044/2017_jslhr-s-16-0460] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/22/2016] [Accepted: 06/17/2017] [Indexed: 06/07/2023]
Abstract
PURPOSE The aim of this study was to add further knowledge about the usefulness of the Voice Range Profile (VRP) assessment in clinical settings and research by analyzing VRP dual-microphone equipment precision, reliability, and room effect. METHOD Test-retest studies were conducted in an anechoic chamber and an office: (a) comparing sound pressure levels (SPLs) from a dual-microphone VRP device, the Voice Profiler, when given the same input repeatedly (test-retest reliability); (b) comparing SPLs from 3 devices when given the same input repeatedly (intervariation); and (c) assessing the room effect. RESULTS (a) The mean standard deviation across 17 measurement points was 0.7 dB for 1 device. (b) One device was less precise than the other 2 devices. All devices presented high SPLs at low frequencies compared with the reference. (c) Mean SPLs were almost equal in the anechoic chamber and the office. CONCLUSIONS The high test-retest reliability of the dual-microphone VRP equipment, especially in general office surroundings, is a positive finding. Attention must be paid to specific factors such as using the same device when comparing the same voice before and after treatment, caution in headset placement, and manual recalibrations when automatic recalibration occurs. We suggest recalibrations verified with a reference source at regular intervals.
Collapse
Affiliation(s)
- Trine Printz
- Department of ENT Head & Neck Surgery, Institute of Clinical Research, Odense University Hospital, Denmark
| | | | - Peter Juhl
- Maersk Mc-Kinney Moller Institute, University of Southern Denmark, Odense
| | - Troels Nielsen
- Maersk Mc-Kinney Moller Institute, University of Southern Denmark, Odense
| | - Ågot Møller Grøntved
- Department of ENT Head & Neck Surgery, Institute of Clinical Research, Odense University Hospital, Denmark
| | - Christian Godballe
- Department of ENT Head & Neck Surgery, Institute of Clinical Research, Odense University Hospital, Denmark
| |
Collapse
|
21
|
Hodges LD, Nielsen T, Baken D. Physiological measures in participants with chronic fatigue syndrome, multiple sclerosis and healthy controls following repeated exercise: a pilot study. Clin Physiol Funct Imaging 2017; 38:639-644. [DOI: 10.1111/cpf.12460] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2016] [Accepted: 06/27/2017] [Indexed: 01/08/2023]
Affiliation(s)
- L. D. Hodges
- School of Sport and Exercise; Massey University; Palmerston North New Zealand
| | - T. Nielsen
- School of Sport and Exercise; Massey University; Palmerston North New Zealand
| | - D. Baken
- School of Psychology; Massey University; Palmerston North New Zealand
| |
Collapse
|
22
|
Klanova M, Sehn L, Bence-Bruckler I, Cavallo F, Jin J, Martelli M, Stewart D, Vitolo U, Zaja F, Zhang Q, Mattiello F, Oestergaard M, Fingerle-Rowson G, Nielsen T, Trneny M. CELL OF ORIGIN COMBINED WITH CNS INTERNATIONAL PROGNOSTIC INDEX IMPROVES IDENTIFICATION OF DLBCL PATIENTS WITH HIGH CNS RELAPSE RISK AFTER INITIAL IMMUNOCHEMOTHERAPY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_25] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M. Klanova
- 1st Department of Medicine, Charles University General Hospital; Prague, Czech Republic and Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd.; Basel Switzerland
| | - L.H. Sehn
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver Canada
| | - I. Bence-Bruckler
- Ottawa Hospital Research Institute; The Ottawa Hospital; Ottawa Canada
| | - F. Cavallo
- Ematologia 1; A.O. Universitaria S. Giovanni Battista-Molinette Di Torino; Torino Italy
| | - J. Jin
- The First Affiliated Hospital of College of Medicine; Zhejiang University; Wenzhou China
| | - M. Martelli
- Department of Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - D. Stewart
- Department of Oncology; Tom Baker Cancer Centre; Calgary Canada
| | - U. Vitolo
- S.C. Ematologia; A.O.U. Citta' Della Salute e della Scienza P.O. Molinette; Turino Italy
| | - F. Zaja
- Oncologia; Clinica Ematologica, ASUI UD S.M. Misericordia di Udine; Udine Italy
| | - Q. Zhang
- Department of Medical Oncology; Harbin Medical University Cancer Hospital; Harbin China
| | - F. Mattiello
- Pharma Development Biometrics Biostatistics; F. Hoffmann-La Roche Ltd.; Basel Switzerland
| | - M.Z. Oestergaard
- Oncology Biomarker Development; F. Hoffmann-La Roche Ltd.; Basel Switzerland
| | - G.R. Fingerle-Rowson
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd.; Basel Switzerland
| | - T. Nielsen
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd.; Basel Switzerland
| | - M. Trneny
- 1st Department of Medicine; Charles University General Hospital; Prague Czech Republic
| |
Collapse
|
23
|
Trotman J, Barrington S, Belada D, Meignan M, MacEwan R, Owen C, Ptáčník V, Rosta A, Fingerle-Rowson G, Mattiello F, Nielsen T, Sahin D, Hiddemann W, Marcus R, Davies A. PROGNOSTIC VALUE OF PET-CT AFTER FIRST-LINE IMMUNOCHEMOTHERAPY FOR FOLLICULAR LYMPHOMA IN THE PHASE III GALLIUM STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_20] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- J. Trotman
- Haematology Department; Concord Repatriation General Hospital; Sydney Australia
| | - S. Barrington
- KCL and Guys' & St Thomas PET Imaging Centre, Division of Imaging and Biomedical Engineering; Kings College London; London UK
| | - D. Belada
- 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove, and Charles University in Prague; Faculty of Medicine in Hradec Kralove; Hradec Kralove Czech Republic
| | - M. Meignan
- Service de Médecine Nucléaire; Hôpital Henri Mondor and Université Paris Est Créteil; Créteil France
| | - R. MacEwan
- Cross Cancer Institute; University of Alberta; Edmonton Canada
| | - C. Owen
- Division of Hematology and Hematological Malignancies; Foothills Medical Centre and Tom Baker Cancer Centre; Calgary Canada
| | - V. Ptáčník
- Department of Nuclear Medicine, First Faculty of Medicine; Charles University; Prague Czech Republic
| | - A. Rosta
- Department of Medicine; National Institute of Oncology; Budapest Hungary
| | - G. Fingerle-Rowson
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - F. Mattiello
- Pharma Development Biometrics Biostatistics; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - T. Nielsen
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - D. Sahin
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - W. Hiddemann
- Medical Department III; Ludwig-Maximilians-University Hospital Munich; Munich Germany
| | - R. Marcus
- Department of Haematology; Kings College Hospital; London UK
| | - A. Davies
- Cancer Research UK Centre; University of Southampton; Southampton UK
| |
Collapse
|
24
|
Kostakoglu L, Martelli M, Belada D, Carella A, Chua N, Gonzalez-Barca E, Hong X, Pinto A, Sehn L, Shi Y, Tatsumi Y, Fingerle-Rowson G, Mattiello F, Nielsen T, Sahin D, Vitolo U, Trněný M. END OF TREATMENT PET-CT PREDICTS PROGRESSION-FREE SURVIVAL IN DLBCL AFTER FIRST-LINE TREATMENT: RESULTS FROM THE PHASE III GOYA STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_45] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- L. Kostakoglu
- Department of Radiology; Icahn School of Medicine at Mount Sinai; New York USA
| | - M. Martelli
- Department of Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - D. Belada
- 4th Department of Internal Medicine-Hematology; University Hospital Hradec Kralove, and Charles University in Prague, Faculty of Medicine in Hradec Kralove; Hradec Kralove Czech Republic
| | - A.M. Carella
- U.O. Hematology I; IRCCS AO University, San Martino-IST; Genoa Italy
| | - N. Chua
- Cross Cancer Institute; University of Alberta; Edmonton Canada
| | - E. Gonzalez-Barca
- Institut Catalá d'Oncologia Hospitalet, IDIBELL; University of Barcelona; Barcelona Spain
| | - X. Hong
- Department of Medical Oncology; Fudan University Shanghai Cancer Center; Shanghai China
| | - A. Pinto
- Istituto Nazionale Tumori, Fondazione G. Pascale; IRCCS; Naples Italy
| | - L.H. Sehn
- Centre for Lymphoid Cancer; British Columbia Cancer Agency and the University of British Columbia; Vancouver Canada
| | - Y. Shi
- National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; Beijing China
| | - Y. Tatsumi
- Department of Hematology and Rheumatology, Faculty of Medicine; Kinki University Hospital; Osaka Japan
| | - G. Fingerle-Rowson
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - F. Mattiello
- Pharma Development Biometrics Biostatistics; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - T. Nielsen
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - D. Sahin
- Department of Hematology and Rheumatology, Faculty of Medicine; Kinki University Hospital; Osaka Japan
| | - U. Vitolo
- Department of Hematology; Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino; Turin Italy
| | - M. Trněný
- Department of Medicine-Department of Hematology; Charles University; Prague Czech Republic
| |
Collapse
|
25
|
Sehn L, Oestergaard M, Trněný M, Bosi A, Egyed M, Illes A, Nakamae H, Opat S, Topp M, Zaja F, Fingerle-Rowson G, Lei G, Nielsen T, Punnoose E, Rahman M, Ray J, Zhang L, Martelli M, Vitolo U. PROGNOSTIC IMPACT OF BCL2 AND MYC EXPRESSION AND TRANSLOCATION IN UNTREATED DLBCL: RESULTS FROM THE PHASE III GOYA STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_121] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- L.H. Sehn
- Centre for Lymphoid Cancer; British Columbia Cancer Agency and the University of British Columbia; Vancouver Canada
| | - M.Z. Oestergaard
- Oncology Biomarker Development; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - M. Trněný
- Charles University; General Hospital; Prague Czech Republic
| | - A. Bosi
- Department of Hematology; Azienda Ospedaliero Universitaria Careggi; Florence Italy
| | - M. Egyed
- Department of Hematology; Kaposi Mor Teaching Hospital; Kaposvár Hungary
| | - A. Illes
- Department of Hematology; University of Debrecen, Faculty of Medicine; Debrecen Hungary
| | - H. Nakamae
- Department of Hematology; Osaka City University Hospital; Osaka Japan
| | - S. Opat
- Department of Clinical Haematology; Monash Health and Monash University; Melbourne Australia
| | - M. Topp
- Department of Haematology, Medizinische Klinik und Poliklinik II; Universitätsklinikum Würzburg; Würzburg Germany
| | - F. Zaja
- Department of Hematology, ASUIUD S. M. Misericordia; Udine Italy
| | - G. Fingerle-Rowson
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - G. Lei
- Department of Biostatistics, Roche Products Ltd; Welwyn Garden City UK
| | - T. Nielsen
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - E.A. Punnoose
- Oncology Biomarker Development; Genentech Inc.; South San Francisco USA
| | - M. Rahman
- Department of Biostatistics, Roche Products Ltd; Welwyn Garden City UK
| | - J. Ray
- Oncology Biomarker Development; Genentech Inc.; South San Francisco USA
| | - L. Zhang
- Department of Pathology; Ventana Medical Systems Inc.; Tucson USA
| | - M. Martelli
- Department of Cellular Biotechnologies and Haematology; Sapienza University; Rome Italy
| | - U. Vitolo
- Department of Hematology; Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino; Turin Italy
| |
Collapse
|
26
|
Fornecker L, Ou F, Dixon J, Casulo C, Hoster E, Hiddemann W, Sebban C, Morschhauser F, Marcus R, Hochster H, Rummel M, Hagenbeeck A, Kimby E, Herold M, Peterson B, Gyan E, Ladetto M, Zucca E, Nielsen T, Foon K, Vitolo U, Flowers C, Shi Q, Salles G. CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES FOR YOUNG PATIENTS WITH FIRST-LINE FOLLICULAR LYMPHOMA: A POOLED ANALYSIS OF 4249 PATIENTS FROM THE FLASH DATABASE. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_89] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- L. Fornecker
- Department of Hematology; University Hospital of Strasbourg; Strasbourg France
| | - F. Ou
- Division of Biomedical Statistics and Informatics, Mayo Clinic; Rochester USA
| | - J.G. Dixon
- Division of Biomedical Statistics and Informatics, Mayo Clinic; Rochester USA
| | - C. Casulo
- School of Medicine and Dentistry; University of Rochester Medical Center; Rochester USA
| | - E. Hoster
- Department of Internal Medicine III; Ludwig-Maximilians University Hospital, Campus Großhadern; Munich Germany
| | - W. Hiddemann
- Department of Internal Medicine III; Ludwig-Maximilians University Hospital, Campus Großhadern; Munich Germany
| | - C. Sebban
- Onco-Hematology, Centre Leon Berard; University Claude Bernard Lyon 1; Lyon France
| | - F. Morschhauser
- Department of Clinical Hematology; Centre Hospitalier Universitaire, Université de Lille; Lille France
| | - R. Marcus
- Department of Haematology; Addenbrookes Hospital; Cambridge UK
| | - H. Hochster
- Yale Cancer Center; Department of Medicine; New Haven USA
| | - M. Rummel
- Medizinische Klinik IV; University Hospital; Gießen Germany
| | - A. Hagenbeeck
- Department of Hematology; Academic Medical Center; Amsterdam The Netherlands
| | - E. Kimby
- Hematology Centre at Karolinska University Hospital; Karolinska Institutet; Stockholm Sweden
| | - M. Herold
- Department of Hematology and Oncology, HELIOS Klinikum; Erfurt Germany
| | - B.A. Peterson
- Division of Hematology, Oncology and Transplantation; University of Minnesota; Minneapolis USA
| | - E. Gyan
- Department of Hematology and Cell Therapy; University Hospital; Tours France
| | - M. Ladetto
- Department of Hematology, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo; Alessandria Italy
| | - E. Zucca
- Department of Hematology, Oncology Institute of Southern Switzerland (IOSI); Bellinzona Switzerland
| | - T. Nielsen
- Department of Medical Affairs; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - K. Foon
- Department of Medical Affairs, Celgene Corporation; Summit USA
| | - U. Vitolo
- Department of Hematology; Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino; Torino Italy
| | - C.R. Flowers
- Department of Bone Marrow and Stem Cell Transplantation; Winship Cancer Institute of Emory University; Atlanta USA
| | - Q. Shi
- Division of Biomedical Statistics and Informatics, Mayo Clinic; Rochester USA
| | - G. Salles
- Department of Hematology; Centre Hospitalier Lyon-Sud; Pierre-Benite France
| |
Collapse
|
27
|
Hiddemann W, Barbui A, Canales Albendea M, Cannell P, Collins G, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Tobinai K, Burciu A, Fingerle-Rowson G, Nielsen T, Wolbers M, Marcus R. IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMISED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_106] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- W. Hiddemann
- Department of Medicine III; Ludwig-Maximilians-University Hospital Munich; Munich Germany
| | - A.M. Barbui
- Department of Hematology; Azienda Ospedaliera Papa Giovanni XXIII; Bergamo Italy
| | | | - P.K. Cannell
- Haematology Department; Fiona Stanley Hospital; Murdoch Australia
| | - G.P. Collins
- Department of Clinical Haematology; Oxford Cancer and Haematology Centre, Churchill Hospital; Oxford UK
| | - J. Dürig
- Medical Faculty (Haematology), Universitaetsklinikum Essen; Essen Germany
| | - R. Forstpointner
- Department of Medicine III; Ludwig-Maximilians-University Hospital Munich; Munich Germany
| | - M. Herold
- Oncology Center; HELIOS-Klinikum Erfurt; Erfurt Germany
| | - M. Hertzberg
- Department of Haematology; Prince of Wales Hospital; Sydney Australia
| | - M. Klanova
- 1st Department of Medicine; Charles University General Hospital, Prague, Czech Republic and Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - J.A. Radford
- Manchester Academic Health Science Centre; The University of Manchester and The Christie NHS Foundation Trust; Manchester UK
| | - K. Tobinai
- Department of Hematology; National Cancer Center Hospital; Tokyo Japan
| | - A. Burciu
- Pharma Development Safety and Risk Management; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - G.R. Fingerle-Rowson
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - T. Nielsen
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - M. Wolbers
- Pharma Development Biometrics Biostatistics; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - R. Marcus
- Department of Haematology; Kings College Hospital; London UK
| |
Collapse
|
28
|
Iversen A, Busk M, Bertelsen L, Laustsen C, Munch O, Nielsen T, Wittenborn T, Bussink J, Lok J, Stødkilde-Jørgensen H, Horsman M. PV-0369: The potential of hyperpolarized 13 C MRS to monitor the effect of vascular disrupting agents. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)30811-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
29
|
Marquis L, Julien S, Blanchette-Carrière C, Baril A, Desjardins M, Carr M, Paquette T, Soucy J, Montplaisir J, Nielsen T. 0732 NIGHTMARE DISTRESS IS NEGATIVELY CORRELATED WITH REGIONAL CEREBRAL BLOOD FLOW IN FRONTAL AREAS DURING AN IAPS PICTURE-VIEWING TASK. Sleep 2017. [DOI: 10.1093/sleepj/zsx050.731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
30
|
Verger E, Nielsen T, Chakaroun R, Aron-Wisnewsky J, Delaere F, Gausserès N, Clément K, Holmes B. Évaluation de la validité relative du questionnaire de fréquence alimentaire développé pour les sujets français de l’étude MetaCardis. NUTR CLIN METAB 2017. [DOI: 10.1016/j.nupar.2016.10.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
31
|
Pinós T, de Luna N, Brull A, Nielsen T, Krag T, Vissing J. New advances in McArdle disease: Characterization of the p.R50X knock-in mouse model and evaluation of new therapeutic approaches. Neuromuscul Disord 2016. [DOI: 10.1016/j.nmd.2016.06.409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
32
|
Nielsen T, Pinos T, Krag T, Vissing J. Effect of treatment with grow factors on muscle pathology in the mdx mouse model of Duchenne muscular dystrophy. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
33
|
Krag T, Pinos T, Nielsen T, Brull A, Andreu A, Vissing J. Molecular, morphological and physiological studies in a mouse model of McArdle disease: Similarities to the human disease. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
34
|
Rasmussen ER, Lykke E, Wagner N, Nielsen T, Waersted S, Arndal H. The introduction of sialendoscopy has significantly contributed to a decreased number of excised salivary glands in Denmark. Eur Arch Otorhinolaryngol 2015; 273:2223-30. [DOI: 10.1007/s00405-015-3755-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2015] [Accepted: 08/13/2015] [Indexed: 10/23/2022]
|
35
|
Gnant M, Sestak I, Filipits M, Dowsett M, Balic M, Lopez-Knowles E, Greil R, Dubsky P, Stoeger H, Rudas M, Jakesz R, Ferree S, Cowens JW, Nielsen T, Schaper C, Fesl C, Cuzick J. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. Ann Oncol 2015; 26:1685-91. [PMID: 25935792 DOI: 10.1093/annonc/mdv215] [Citation(s) in RCA: 90] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2014] [Accepted: 04/24/2015] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND In the adjuvant treatment of hormone receptor-positive (HR+) breast cancer, variables like tumour size, grade and nodal status have great impact on therapy decisions. As most node-positive patients with HR+ breast cancer currently receive adjuvant chemotherapy improved methods for characterization of individuals' metastasis risk are needed to reduce overtreatment. PATIENTS AND METHODS Tissue specimens from node-positive patients of the ABCSG-8 and ATAC trials who received adjuvant tamoxifen and/or anastrozole were included in this study. Analysing RNA from paraffin blocks using the PAM50 test, the primary objective was to evaluate the prognostic information of the risk of recurrence (ROR) score added to combined clinical standard variables in patients with one positive node (1N+) and in patients with two or three positive nodes (2-3N+), using log-likelihood ratio tests. RESULTS At a median follow-up of 9.6 years, distant metastases occurred in 97 (18%) of 543 node-positive patients. In a multivariate analysis, the PAM50-derived ROR score provided reliable prognostic information in addition to and beyond established clinical factors for 1N+ (P < 0.0001) and 2-3N+ patients (P = 0.0002). Ten-year distant recurrence risk was significantly increased in the high-risk compared with the low-risk group derived from ROR score for 1N+ [25.5%, 95% confidence interval (CI) 17.5% to 36.1%versus 6.6%, 95% CI 3.3% to 12.8%] and compared with the combined low/intermediate risk group for 2-3N+ patients (33.7%, 95% CI 25.5% to 43.8% versus 12.5%, 95% CI 6.6% to 22.8%). Additionally, the luminal A intrinsic subtype (IS) exhibited significantly lower risk of distant recurrence compared with the luminal B subtype in 1N+ and 2-3N+ patients. CONCLUSION PAM50 ROR score and IS can identify node-positive patient subgroups with limited risk of metastasis after endocrine therapy, for whom adjuvant chemotherapy can be spared. The PAM50 test is a valuable tool in determining treatment of node-positive early-stage breast cancer patients.
Collapse
Affiliation(s)
- M Gnant
- Department of Surgery and Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria
| | - I Sestak
- Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK
| | - M Filipits
- Department of Medicine I, Medical University of Vienna, Vienna, Austria
| | - M Dowsett
- Academic Department of Biochemistry, Royal Marsden Hospital and Breakthrough Breast Cancer Centre, London, UK
| | - M Balic
- Department of Internal Medicine, Medical University Graz, Graz, Austria
| | - E Lopez-Knowles
- Institute of Cancer Research, Royal Marsden Hospital and Breakthrough Breast Cancer Research Centre, London, UK
| | - R Greil
- Department of Internal Medicine III, Paracelsus Medical University Salzburg, Salzburg
| | - P Dubsky
- Department of Surgery and Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria
| | - H Stoeger
- Department of Internal Medicine, Medical University Graz, Graz, Austria
| | - M Rudas
- Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria
| | - R Jakesz
- Department of Surgery and Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria
| | - S Ferree
- NanoString Technologies, Seattle, USA
| | | | - T Nielsen
- Department of Pathology, University of British Columbia, Vancouver, Canada
| | - C Schaper
- Independent Statistical Consultant New York, New York, USA
| | - C Fesl
- Department of Statistics, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria
| | - J Cuzick
- Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK
| |
Collapse
|
36
|
Kallehauge J, Nielsen T, Alber M, Haack S, Pedersen E, Lindegaard J, Ramlov A, Tanderup K. PD-0144: Classification of tumor sub-volumes based on Dynamic Contrast Enhanced MRI model hierarchy for cervical cancer. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)40142-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
37
|
Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015; 26:259-271. [PMID: 25214542 PMCID: PMC6267863 DOI: 10.1093/annonc/mdu450 10.1097/pai.0000000000000594] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2014] [Accepted: 08/28/2014] [Indexed: 04/29/2024] Open
Abstract
BACKGROUND The morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer (BC) is gaining momentum as evidence strengthens for the clinical relevance of this immunological biomarker. Accumulating evidence suggests that the extent of lymphocytic infiltration in tumor tissue can be assessed as a major parameter by evaluation of hematoxylin and eosin (H&E)-stained tumor sections. TILs have been shown to provide prognostic and potentially predictive value, particularly in triple-negative and human epidermal growth factor receptor 2-overexpressing BC. DESIGN A standardized methodology for evaluating TILs is now needed as a prerequisite for integrating this parameter in standard histopathological practice, in a research setting as well as in clinical trials. This article reviews current data on the clinical validity and utility of TILs in BC in an effort to foster better knowledge and insight in this rapidly evolving field, and to develop a standardized methodology for visual assessment on H&E sections, acknowledging the future potential of molecular/multiplexed approaches. CONCLUSIONS The methodology provided is sufficiently detailed to offer a uniformly applied, pragmatic starting point and improve consistency and reproducibility in the measurement of TILs for future studies.
Collapse
Affiliation(s)
- R Salgado
- Breast Cancer Translational Research Laboratory/Breast International Group, Institut Jules Bordet, Brussels Department of Pathology and TCRU, GZA, Antwerp, Belgium
| | - C Denkert
- Institute of Pathology, Charité -University Hospital, Berlin, Germany
| | - S Demaria
- Perlmutter Cancer Center, New York University Medical School, New York, USA
| | - N Sirtaine
- Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - F Klauschen
- Institute of Pathology, Charité -University Hospital, Berlin, Germany
| | - G Pruneri
- European Institute of Oncology (IEO) and University of Milan, Milan, Italy
| | - S Wienert
- Institute of Pathology, Charité -University Hospital, Berlin, Germany
| | - G Van den Eynden
- Department of Pathology GZA, TCRU Hospitals and CORE Antwerp University, Antwerp, Belgium
| | - F L Baehner
- Genomic Health, Inc., Redwood City, USA University of California San Francisco, San Francisco, USA
| | - F Penault-Llorca
- Clermont-Ferrand Biopathology, University of Auvergne, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France
| | - E A Perez
- Division of Haematology/Medical Oncology and
| | - E A Thompson
- Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville
| | - W F Symmans
- Department of Pathology, The UT M.D. Anderson Cancer Center, Boston
| | - A L Richardson
- Department of Pathology, Brigham and Women's Hospital, Boston Department of Cancer Biology, Dana Farber Cancer Institute, Boston
| | - J Brock
- Department of Cancer Biology, Dana Farber Cancer Institute, Boston Department of Cancer Biology, Harvard Medical School, Boston, USA
| | | | - H Bailey
- Genomic Health, Inc., Redwood City, USA
| | - M Ignatiadis
- Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels
| | - G Floris
- Department of Pathology, University Hospital Leuven, Leuven, Belgium
| | - J Sparano
- Department of Medicine, Department of Obstetrics and Gynecology and Women's Health, Albert Einstein Medical Center, Bronx, USA
| | - Z Kos
- Laboratory Medicine Program, University Health Network, University of Toronto, Toronto
| | - T Nielsen
- Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
| | - D L Rimm
- Department of Pathology, Yale University School of Medicine, New Haven
| | - K H Allison
- Department of Pathology, Stanford University Medical Centre, Stanford
| | - J S Reis-Filho
- Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - S Loibl
- German Breast Group, Neu-Isenburg, Germany
| | - C Sotiriou
- Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels
| | - G Viale
- Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy
| | - S Badve
- Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, USA
| | - S Adams
- Perlmutter Cancer Center, New York University Medical School, New York, USA
| | - K Willard-Gallo
- Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - S Loi
- Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Victoria, Australia
| |
Collapse
|
38
|
Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2014; 26:259-71. [PMID: 25214542 DOI: 10.1093/annonc/mdu450] [Citation(s) in RCA: 1861] [Impact Index Per Article: 186.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND The morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer (BC) is gaining momentum as evidence strengthens for the clinical relevance of this immunological biomarker. Accumulating evidence suggests that the extent of lymphocytic infiltration in tumor tissue can be assessed as a major parameter by evaluation of hematoxylin and eosin (H&E)-stained tumor sections. TILs have been shown to provide prognostic and potentially predictive value, particularly in triple-negative and human epidermal growth factor receptor 2-overexpressing BC. DESIGN A standardized methodology for evaluating TILs is now needed as a prerequisite for integrating this parameter in standard histopathological practice, in a research setting as well as in clinical trials. This article reviews current data on the clinical validity and utility of TILs in BC in an effort to foster better knowledge and insight in this rapidly evolving field, and to develop a standardized methodology for visual assessment on H&E sections, acknowledging the future potential of molecular/multiplexed approaches. CONCLUSIONS The methodology provided is sufficiently detailed to offer a uniformly applied, pragmatic starting point and improve consistency and reproducibility in the measurement of TILs for future studies.
Collapse
Affiliation(s)
- R Salgado
- Breast Cancer Translational Research Laboratory/Breast International Group, Institut Jules Bordet, Brussels Department of Pathology and TCRU, GZA, Antwerp, Belgium
| | - C Denkert
- Institute of Pathology, Charité -University Hospital, Berlin, Germany
| | - S Demaria
- Perlmutter Cancer Center, New York University Medical School, New York, USA
| | - N Sirtaine
- Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - F Klauschen
- Institute of Pathology, Charité -University Hospital, Berlin, Germany
| | - G Pruneri
- European Institute of Oncology (IEO) and University of Milan, Milan, Italy
| | - S Wienert
- Institute of Pathology, Charité -University Hospital, Berlin, Germany
| | - G Van den Eynden
- Department of Pathology GZA, TCRU Hospitals and CORE Antwerp University, Antwerp, Belgium
| | - F L Baehner
- Genomic Health, Inc., Redwood City, USA University of California San Francisco, San Francisco, USA
| | - F Penault-Llorca
- Clermont-Ferrand Biopathology, University of Auvergne, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France
| | - E A Perez
- Division of Haematology/Medical Oncology and
| | - E A Thompson
- Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville
| | - W F Symmans
- Department of Pathology, The UT M.D. Anderson Cancer Center, Boston
| | - A L Richardson
- Department of Pathology, Brigham and Women's Hospital, Boston Department of Cancer Biology, Dana Farber Cancer Institute, Boston
| | - J Brock
- Department of Cancer Biology, Dana Farber Cancer Institute, Boston Department of Cancer Biology, Harvard Medical School, Boston, USA
| | | | - H Bailey
- Genomic Health, Inc., Redwood City, USA
| | - M Ignatiadis
- Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels
| | - G Floris
- Department of Pathology, University Hospital Leuven, Leuven, Belgium
| | - J Sparano
- Department of Medicine, Department of Obstetrics and Gynecology and Women's Health, Albert Einstein Medical Center, Bronx, USA
| | - Z Kos
- Laboratory Medicine Program, University Health Network, University of Toronto, Toronto
| | - T Nielsen
- Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada
| | - D L Rimm
- Department of Pathology, Yale University School of Medicine, New Haven
| | - K H Allison
- Department of Pathology, Stanford University Medical Centre, Stanford
| | - J S Reis-Filho
- Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - S Loibl
- German Breast Group, Neu-Isenburg, Germany
| | - C Sotiriou
- Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels
| | - G Viale
- Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy
| | - S Badve
- Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, USA
| | - S Adams
- Perlmutter Cancer Center, New York University Medical School, New York, USA
| | - K Willard-Gallo
- Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - S Loi
- Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Victoria, Australia
| | | |
Collapse
|
39
|
Nordström CH, Nielsen T, Nielsen H. Lactate uptake against a concentration gradient: misinterpretation of analytical imprecision. J Neurotrauma 2014; 31:1528. [PMID: 24417687 DOI: 10.1089/neu.2013.3229] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Carl-Henrik Nordström
- Department of Neurosurgery, Odense University Hospital, Institute of Clinical Science , Odense, Denmark
| | | | | |
Collapse
|
40
|
Kallehauge J, Haack S, Tanderup K, Lindegaard J, Mohamed S, Pedersen E, Fokdal L, Nielsen T. PD-0414: Tracer kinetic model selection for dynamic contrast-enhanced MRI of locally advanced cervical cancer. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)30519-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
41
|
Bonde L, Vilsbøll T, Nielsen T, Bagger JI, Svare JA, Holst JJ, Larsen S, Knop FK. Reduced postprandial GLP-1 responses in women with gestational diabetes mellitus. Diabetes Obes Metab 2013; 15:713-20. [PMID: 23406269 DOI: 10.1111/dom.12082] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/31/2012] [Revised: 10/24/2012] [Accepted: 01/20/2013] [Indexed: 01/23/2023]
Abstract
AIM We investigated postprandial glucagon-like peptide-1 (GLP-1) responses in pregnant women with and without gestational diabetes mellitus (GDM) and again following delivery when normal glucose tolerance (NGT) was re-established. METHODS Eleven women with GDM [plasma glucose (PG) concentration at 120 min after a 75-g oral glucose tolerance test (OGTT): 10.0 ± 0.9 mM (mean ± SD); age: 31 ± 6 years; body mass index (BMI): 31.6 ± 6.4 kg/m(2) ; haemoglobin A1c (HbA1c): 5.6 ± 0.5%] and eight pregnant women with NGT (PG(120 min), OGTT : 5.7 ± 0.7 mM; age: 28 ± 3 years; BMI: 29.7 ± 5.4 kg/m(2) ; HbA1c: 5.4 ± 0.3%) were investigated with a 4-h liquid meal test during third trimester (TT) and 3-4 months postpartum (PP). All patients with GDM re-established NGT following delivery. RESULTS Pregnancy was associated with low postprandial GLP-1 responses. Patients with GDM exhibited reduced postprandial GLP-1 responses compared to their PP levels [area under curve (AUC): 5.5 ± 1.3 vs. 8.4 ± 3.2 nM × min, p=0.005], but the difference among NGT women (7.3 ± 2.8 vs. 8.8 ± 2.0 nM × min, p=0.066) was not statistically significant. Pregnancy did not influence postprandial responses of the other incretin hormone glucose-dependent insulinotropic polypeptide (GIP) in any of the groups, but GDM patients were characterized by greater postprandial GIP responses during both TT and PP compared to NGT subjects. CONCLUSIONS Pregnancy is associated with reduced postprandial GLP-1 responses (most pronounced in patients with GDM) that normalize after delivery. In contrast, postprandial GIP responses seem unaffected by pregnancy but is increased in GDM patients.
Collapse
Affiliation(s)
- L Bonde
- Department of Internal Medicine, Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Abstract
BACKGROUND/AIM We studied all patients admitted to hospital with first onset atrial fibrillation (AF) to determine the probability of spontaneous conversion to sinus rhythm and to identify factors predictive of such a conversion. METHODS We retrospectively reviewed charts of 438 consecutive patients admitted to hospital with first onset AF from 1 January 2006 to 31 December 2009. The patients were divided into two groups, recent onset AF defined as AF < 48 h or longer lasting AF, defined as AF > 48 h. RESULTS Spontaneous conversion occurred in 54% (n = 203; 95% confidence interval: 49-59%). In the group with first onset AF < 48 h, spontaneous conversion occurred in 77%, compared with 36% in the group with first onset AF > 48 h. Logistic regression analysis identified duration of AF as a highly significant predictor of spontaneous conversion to sinus rhythm (odds ratio 5.9; 95% confidence interval: 4.0-8.6, P < 0.001). CONCLUSIONS Spontaneous conversion occurred in 54%, increasing to 77% when AF had persisted less than 48 h.
Collapse
Affiliation(s)
- S Lindberg
- Geriatric Department, Roskilde Hospital, Roskilde, Denmark.
| | | | | |
Collapse
|
43
|
Gnant M, Filipits M, Dubsky P, Rudas M, Balic M, Greil R, Ferree S, Cowens J, Schaper C, Nielsen T. Predicting Risk for Late Metastasis: the PAM50 Risk of Recurrence (ROR) Score After 5 Years of Endocrine Therapy in Postmenopausal Women with Hr+ Early Breast Cancer: a Study On 1,478 Patients from the Abcsg-8 Trial. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt084.1] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Kallehauge J, Haack S, Tanderup K, Nielsen T, Rasmussen F, Fokdal L, Lindegaard J, Pedersen E. OC-0152: Comparison of DWI-MRI and DCE-MRI for locally advanced cervical cancer. Radiother Oncol 2013. [DOI: 10.1016/s0167-8140(15)32458-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
45
|
Cheang MCU, Parker J, DeSchryver K, Snider J, Walsh T, Davies S, Prat A, Vickery T, Reed J, Zehnbauer B, Leung S, Voduc D, Nielsen T, Mardis E, Bernard P, Perou C, Ellis M. Abstract P6-07-10: Luminal A vs. Basal-like Breast Cancer: time dependent changes in the risk of relapse in the absence of treatment. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p6-07-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Numerous retrospective analyses of prospective randomized clinical trials of patients treated with adjuvant tamoxifen and chemotherapy have demonstrated that the breast cancer intrinsic subtype Luminal A tumors generally have favorable early initial outcomes, while basal-like tumors are associated with a marked risk of early relapse. To determine the extended natural history of the intrinsic subtypes across two decades of follow up the PAM50 “non-commercial open source bioinformatics” qPCR assay was conducted on node negative tumors accrued through the Cooperative Breast Cancer Tissue Registry (CBCTR) from patients who did not receive systemic therapy.
Methods: Intrinsic subtype calls were obtained from 331 CBCTR cases treated with local interventions only. Tumors were classified into Luminal A (LumA), Luminal B (LumB), HER2-enriched (HER2-E) and Basal-like (BLBC), and correlated relapse-free (RFS). Patient survival and hazard rate were estimated using Kaplan-Meier plots and log-rank test. Multivariable Cox regression analyses were used to determine the significance of the intrinsic subtypes, adjusted with standard clinicopathological variables including tumor size, age at diagnosis, grade, radiation therapy treatment, centralized reviewed estrogen receptor, progesterone receptor and human epidermal growth factor 2 status measured by immunohistochemistry. Patients were diagnosed from 1978 to 1992, with a mean follow-up time of 13 years (range 0.5–31).
Results: Of the 331 tumors tested, 51% of cases were classified as LumA, 18% as LumB, 11% as HER2-E and 20% as BLBC. Although LumA was associated with the best outcome for the first 10-year of follow-up, the final number of RFS events were eventually comparable with those observed for BLBC with prolonged follow up (Table 1). In the multivariable Cox model, only BLBC tumors were associated with worse prognosis than LumA with borderline significance (Hazard ratio: 2.0 (95% CI 0.9–5), p = 0.07). BLBC had the highest hazard rates for the first 5 years (7% at first year to 5% at 5 yr), consistent with previous observations. Interestingly, in the absence of treatment, the slow growing LumA subtype had a gradual increase of hazard for an RFS event from 3% at 5 yrs to 4% at 10 yrs to 7% at 20 yrs. The hazard rates of LumA cross with those of BLBC at 10 years.
Conclusions: Basal-like breast cancers are associated with an early risk of relapse that decreases over time. In contrast, Luminal A breast cancer has a low risk of relapse at the outset but the risk of relapse increases over time and is responsible of the majority of the RFS events after 20 years of follow up. Luminal A breast cancers are therefore not truly low risk, particularly if they do not receive endocrine therapy; and may experience the consequences of inadequate treatment decades after diagnosis.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-07-10.
Collapse
Affiliation(s)
- MCU Cheang
- University of North Carolina at Chapel Hill, NC; University of British Columbia, Vancouver, BC, Canada; Washington University School of Medicine; University of Utah
| | - J Parker
- University of North Carolina at Chapel Hill, NC; University of British Columbia, Vancouver, BC, Canada; Washington University School of Medicine; University of Utah
| | - K DeSchryver
- University of North Carolina at Chapel Hill, NC; University of British Columbia, Vancouver, BC, Canada; Washington University School of Medicine; University of Utah
| | - J Snider
- University of North Carolina at Chapel Hill, NC; University of British Columbia, Vancouver, BC, Canada; Washington University School of Medicine; University of Utah
| | - T Walsh
- University of North Carolina at Chapel Hill, NC; University of British Columbia, Vancouver, BC, Canada; Washington University School of Medicine; University of Utah
| | - S Davies
- University of North Carolina at Chapel Hill, NC; University of British Columbia, Vancouver, BC, Canada; Washington University School of Medicine; University of Utah
| | - A Prat
- University of North Carolina at Chapel Hill, NC; University of British Columbia, Vancouver, BC, Canada; Washington University School of Medicine; University of Utah
| | - T Vickery
- University of North Carolina at Chapel Hill, NC; University of British Columbia, Vancouver, BC, Canada; Washington University School of Medicine; University of Utah
| | - J Reed
- University of North Carolina at Chapel Hill, NC; University of British Columbia, Vancouver, BC, Canada; Washington University School of Medicine; University of Utah
| | - B Zehnbauer
- University of North Carolina at Chapel Hill, NC; University of British Columbia, Vancouver, BC, Canada; Washington University School of Medicine; University of Utah
| | - S Leung
- University of North Carolina at Chapel Hill, NC; University of British Columbia, Vancouver, BC, Canada; Washington University School of Medicine; University of Utah
| | - D Voduc
- University of North Carolina at Chapel Hill, NC; University of British Columbia, Vancouver, BC, Canada; Washington University School of Medicine; University of Utah
| | - T Nielsen
- University of North Carolina at Chapel Hill, NC; University of British Columbia, Vancouver, BC, Canada; Washington University School of Medicine; University of Utah
| | - E Mardis
- University of North Carolina at Chapel Hill, NC; University of British Columbia, Vancouver, BC, Canada; Washington University School of Medicine; University of Utah
| | - P Bernard
- University of North Carolina at Chapel Hill, NC; University of British Columbia, Vancouver, BC, Canada; Washington University School of Medicine; University of Utah
| | - C Perou
- University of North Carolina at Chapel Hill, NC; University of British Columbia, Vancouver, BC, Canada; Washington University School of Medicine; University of Utah
| | - M Ellis
- University of North Carolina at Chapel Hill, NC; University of British Columbia, Vancouver, BC, Canada; Washington University School of Medicine; University of Utah
| |
Collapse
|
46
|
Madsen T, Christiansen L, Nielsen T, Troelsen J, Schipperijn J, Duncan S. Associations between a walkability index and bicycle use in Denmark. J Sci Med Sport 2012. [DOI: 10.1016/j.jsams.2012.11.657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
47
|
Hilton JF, Dong B, Bouganim N, Chapman JAW, Arnaout A, O'Malley F, Nielsen T, Gelmon K, Yerushalmi R, Levine M, Bramwell V, Whelan T, Pritchard KI, Shepherd L, Clemons M. P2-12-27: Simply Adding Together the Diameters of Tumor Foci in Patients with Multicentric or Multifocal Disease Does Not Add Any Additional Prognostic Information: An Analysis from NCIC CTG MA.12 Randomized Placebo-Controlled Trial of Tamoxifen after Adjuvant Chemotherapy in Pre-Menopausal Women with Early Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p2-12-27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A common clinical conundrum in breast cancer management is whether pathologic T stage in women with multicentric or multifocal disease should be taken as the diameter of the largest focus or as the sum of all foci in the breast. Most staging systems, such as the American Joint Committee on Cancer (AJCC), simply use the largest tumor focus for staging. We examine here the impact of alternate methods of estimating tumour size including measures of total tumor size, volume and surface area.
Materials & Methods: NCIC CTG MA.12 is a randomized placebo-controlled trial of tamoxifen after adjuvant chemotherapy for pre-menopausal women with early breast cancer. Median follow up is 9.7 years. Pathologically reported patient tumor dimensions for up to 3 foci were utilized to examine the effects of tumor size on Breast-Cancer-Free-Interval (BCFI), defined as the time from randomization until recurrence (defined as first local, regional, distant, or contralateral invasive tumor or DCIS). Tumor size was estimated as 1) pathologic T stage as per AJCC criteria; 2) largest dimension of largest tumor focus (cm); 3) sum of largest dimension(s) of tumor foci (cm); 4) sum of surface area(s) of tumor foci (cm2), and 5) sum of volume of tumor foci (cm3). Step-wise forward unstratified Cox regression was used to assess the different effects of tumor size. Results: This study accrued 672 patients, 43% with T1 tumors, 51% with T2 tumors, and 6% with T3/T4 tumors; 25% were node negative and 56% had 1–3 positive lymph nodes. 75% were locally determined to have hormone receptor positive tumors. A higher number of involved lymph nodes was associated with significantly shorter BCFI (p<0.0001). None of pathologic T stage (p=0.14), largest dimension of largest tumor size (p=0.14), sum of largest dimensions of tumor foci (p=0.24), sum of surface area (p=0.38), and sum of volume of foci (p=0.51) were significantly associated with BCFI. Likewise, lymphovascular invasion (p=0.08), grade (p=0.14), nor administration of anthracycline therapy (p=0.08) were associated with BCFI.
Discussion: In the MA.12 population of pre-menopausal women randomized to either tamoxifen or placebo, the sole factor significantly associated with BCFI was nodal status. No measure of tumor size in unifocal or multicentric/multifocal tumors impacted BCFI. The findings of this mature data set suggest that simply adding together the diameters of tumors in patients with multicentric or multifocal disease did not add any additional prognostic information.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-12-27.
Collapse
Affiliation(s)
- JF Hilton
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - B Dong
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - N Bouganim
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - J-AW Chapman
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - A Arnaout
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - F O'Malley
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - T Nielsen
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - K Gelmon
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - R Yerushalmi
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - M Levine
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - V Bramwell
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - T Whelan
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - KI Pritchard
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - L Shepherd
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - M Clemons
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
48
|
Bouganim N, Dong B, Hilton JF, Chapman JAW, Arnaout A, O'Malley F, Nielsen T, Gelmon K, Yerushalmi R, Levine M, Bramwell V, Whelan T, Pritchard KI, Shepherd L, Clemons M. P2-12-23: How Should We Assess Tumour Size (T Stage) in Patients with Multicentric/Multifocal Breast Cancer? Results from the NCIC CTG MA.5 Randomized Trial of CEF vs. CMF in Pre-Menopausal Women with Node Positive Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p2-12-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
A common clinical conundrum in breast cancer management is whether pathologic T stage in women with multicentric or multifocal disease should be taken as the diameter of the largest focus or as the sum of all foci in the breast. Most staging systems, such as the American Joint Committee on Cancer (AJCC), simply use the largest tumour focus for staging. We examine here the impact of alternate methods of estimating tumour size including measures of total tumour size, volume and surface area.
Methods: NCIC CTG MA.5 is a randomized trial of CEF versus CMF in pre-menopausal women with node positive breast cancer.
Median follow up is 10 years. Pathologically reported patient tumour dimensions for up to 3 foci were utilized to examine the effects of tumour size on Breast-Cancer-Free-Interval (BCFI). BCFI is defined as the time from randomization until recurrence: first local invasive or DCIS, regional, distant, contralateral invasive or DCIS. Tumour size was estimated as 1) pathologic T stage as per AJCC criteria; 2) largest dimension of largest tumour focus (cm); 3) sum of largest dimension(s) of tumour foci (cm); 4) sum of surface area(s) of tumour foci (cm2), and 5) sum of volume of tumour foci (cm3). Step-wise forward unstratified Cox regression was used to assess the different effects of tumour size.
Results: This study accrued 710 patients, 37% with T1 tumours, 52% with T2 tumours and 9% with T3 tumours; 61% had 1 to 3 positive lymph nodes. 59% hormone receptor positive. Higher pathologic T stage (p=0.001) and greater surface area (p=0.02) were associated with shorter BCFI, as was lymphovascular invasion (p=0.03), and # of lymph nodes involved (p<0.0001). Administration of anthracycline therapy led to significantly longer BCFI (0.003). The sum of largest tumour sizes (p=0.33) and sum of tumour volume (p=0.34) were not significantly associated with BCFI. Additionally, when the less complete locally reported tumour grade data were included, higher tumour grade was associated with shorter BCFI (p<0.0001).
Conclusions: Consideration of multicentric and multifocal disease was an important adjunct to standard pathologic tumour size as was estimation of tumour surface area in this chemotherapy trial of node positive premenopausal women. However, simply adding together the diameters of tumours in patients with multicentric or multifocal disease did not add any additional prognostic information in this high risk patient population.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-12-23.
Collapse
Affiliation(s)
- N Bouganim
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - B Dong
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - JF Hilton
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - J-AW Chapman
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - A Arnaout
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - F O'Malley
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - T Nielsen
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - K Gelmon
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - R Yerushalmi
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - M Levine
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - V Bramwell
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - T Whelan
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - KI Pritchard
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - L Shepherd
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - M Clemons
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| |
Collapse
|
49
|
Nielsen JC, Thomsen PEB, Hojberg S, Moller M, Riahi S, Dalsgaard D, Mortensen LS, Nielsen T, Asklund M, Friis EV, Christensen PD, Simonsen EH, Eriksen UH, Jensen GVH, Svendsen JH, Toff WD, Healey JS, Andersen HR. Atrial fibrillation in patients with sick sinus syndrome: the association with PQ-interval and percentage of ventricular pacing. Europace 2011; 14:682-9. [DOI: 10.1093/europace/eur365] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
50
|
Nielsen T, Sparsø T, Grarup N, Jørgensen T, Pisinger C, Witte DR, Hansen T, Pedersen O. Type 2 diabetes risk allele near CENTD2 is associated with decreased glucose-stimulated insulin release. Diabetologia 2011; 54:1052-6. [PMID: 21267535 DOI: 10.1007/s00125-011-2054-3] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/17/2010] [Accepted: 12/22/2010] [Indexed: 12/26/2022]
Abstract
AIMS/HYPOTHESIS By combining multiple genome-wide association (GWA) studies and comprehensive replication efforts, 12 novel type 2 diabetes associated loci have recently been discovered. Here we evaluate the effect of lead variants of these loci on estimates of insulin release and insulin resistance derived from an oral glucose tolerance test. METHODS We examined 12 lead variants in or near HMGA2, CENTD2 (also known as ARAP1), KLF14, PRC1, TP53INP1, ZBED3, ZFAND6, CHCHD9, DUSP9, KCNQ1, BCL11A and HNF1A in 5,722 middle-aged people from the population-based Inter99 sample. RESULTS Carriers of the major diabetogenic allele of rs1552224 in CENTD2 had increased 30-min plasma glucose values (2.0%, p = 2 × 10(-5)) as well as 4.2% reduced insulin release 30 min after an oral glucose load (p = 0.001). Risk allele carriers also had decreased BIGTT-acute insulin release (AIR), which is a surrogate measure of insulin release where sex, BMI, plasma glucose and serum insulin are integrated (5.3%, p = 8 × 10(-7)). In addition, a decreased corrected insulin response (CIR; 9.9%, p = 3 × 10(-8)) was observed. For rs5945326 near DUSP9 on the X-chromosome we stratified according to sex. Male carriers of the risk allele showed nominally decreased BIGTT-AIR (2.6%, p = 0.01). No associations with intermediate metabolic traits were found in women. For the remaining ten lead variants no consistent associations were demonstrated. CONCLUSIONS/INTERPRETATION Of the lead variants from 12 novel type 2 diabetes associated loci, CENTD2 significantly associated with increased plasma glucose values and decreased glucose-stimulated insulin release, suggesting that the diabetogenic effect of this locus is mediated through an impaired pancreatic beta cell function.
Collapse
Affiliation(s)
- T Nielsen
- Marie Krogh Center for Metabolic Research, Section of Metabolic Genetics, Faculty of Health Sciences, University of Copenhagen, Universitetsparken 1, 2100 Copenhagen, Denmark.
| | | | | | | | | | | | | | | | | |
Collapse
|